Microsoft word - carter--ccfa--final.doc
HANAUER, STEPHEN B
Dr. Hanauer received funds from CCFA from 1992 to 1995 to carry out a multicenter
evaluation of the efficacy of methotrexate in chronically active CD.
Methotrexate has been proven effective in moderate to severe CD (1) and to maintain
remission in adults with CD (1,2). Hanauer participated in several studies evaluating its efficacy and safety, particularly in maintaining remission.
In a double-blind, placebo-controlled, multicenter trial in patients with active CD who
had entered remission, the investigators found that a significant number of these patients were able to remain in remission long-term (40 wk) on a reduced dose (15 mg IM vs 25 mg IM once weekly), and significantly few needed prednisone because of relapse compared with placebo (3).
In a study of the adverse effects of IBD drugs, the investigators found that
methotrexate carries a range of adverse effects, including nausea, leucopenia, and, rarely, hepatic fibrosis or hypersensitivity pneumonia (4). It is also contraindicated in pregnancy (5). Because of concerns over hepatotoxicity, a study was designed to determine whether surveillance liver biopsies are warranted in IBD (6). The patients (N=20) had experienced long-term methotrexate therapy. Liver biopsies revealed only mild histological abnormalities (Roenigk’s grade I and II) and one case of hepatic fibrosis. Abnormal liver chemistry test results were seen in 30% of patients, none of whom demonstrated Roenigk’s grade IIIB hepatotoxicity. The investigators concluded that surveillance liver biopsies were not warranted for such patients. Because of its adverse effects, however, this agent is considered for second-line therapy in patients who are refractory to or cannot tolerate 6-MP/azathioprine (1).
Hanauer also helped evaluate the steroid-sparing effect of methotrexate in CD in a
study of patients (N=76) with long-term CD (mean: 9.5 y) and methotrexate therapy (mean: 55 wk; mean dose:20 mg/wk). Improvement was seen in 63% after 9 weeks of therapy and lasted 65 weeks, while remission was seen in 37% after 22 weeks of therapy and lasted 59 weeks. The results were best with parenteral therapy and in younger patients (<40 y) (7).
Continued evaluation of this drug is warranted, given the fact that drugs in this
category have already demonstrated their potential for extending the duration of infliximab therapy by keeping the level of infliximab antibodies relatively low (8). This effect, if seen in methotrexate, may indicate the potential for combination therapy. 1. Friedman S. General principles of medical therapy of inflammatory bowel disease.
Gastroenterol Clinics North Am.
2. Hendrickson BA, Ranjana Gokhale, Cho JH. Clinical aspects and pathophysiology of
inflammatory bowel disease. Clin Microbiol Rev.
3. Feagan BG, Fedorak RN, Irvine EJ, et al. A comparison of methotrexate with
placebo for the maintenance of remission in Crohn’s disease. North American Crohn’s Study Group Investigators. N Engl J Med.
4. Stein RB, Hanauer SB. Comparative tolerability of treatments for inflammatory
bowel disease. Drug Saf.
5. Navarro F, Hanauer SB. Treatment of inflammatory bowel disease: safety and
tolerability issues. Am J Gastroenterol.
6. Te HS, Schiano TD, Kuan SF, Hanauer SB, Conjeevaram HS, Baker AL. Hepatic
effects of long-term methotrexate use in the treatment of inflammatory bowel disease. Am J Gastroenterol.
7. Chong RY, Hanauer SB, Cohen RD. Efficacy of parenteral methotrexate in refractory
Crohn’s disease. Aliment Pharmacol Ther.
8. Bickston SJ, Lawrence WC, Cominelli F. Future therapies for inflammatory bowel
disease. Curr Gastroenterol Rep.
KORELITZ, BURTON I, MD
Korelitz received funds from CCFA from 1993 through 1995 to develop a double-
blind, randomized trial of 6-MP versus 5 aminosalicylic acid in the prevention of recurrent ileitis after resection in patients with CD.
Judge and Lichtenstein cited studies in which Korelitz participated to indicate that
complete 6-MP may be helpful for achieving fistula closure (1) or to complete fistula healing and remission (2). These studies were also used to identify any serious adverse events that can result from 6-MP therapy (3).
Markowitz (4,5) and Dubinsky (6) cited studies by Korelitz indicating that
azathioprine and 6-MP are efficacious in patients with CD who develop fistulas. Markowitz also cited studies by Korelitz and colleagues providing anecdotal and trial evidence that 6-MP reduces the rate of postsurgical endoscopic (6 mo) and clinical (12 mo) relapse.
The results of a 1993 study of mesalamine monotherapy in patients intolerant of the
parent drug (sulfasalazine), in which Korelitz participated, indicated that the drug was effective in both CD and UC, and that it was more effective than the parent drug in CD (7).
Korelitz participated in a 2-year study comparing 6-MP, 5-aminosalicylic acid, and
placebo in preventing the postoperative recurrence of CD (8). The results, reported in 2004, indicated that the recurrence rate was lowest with 6-MP compared with mesalamine and placebo, whether recurrence was evaluated clinically (50%, 58%, and 77%, respectively), endoscopically (43%, 63%, and 64%, respectively), or radiographically (33%, 46%, and 49%, respectively).
Thus, although both agents are safe and effective in CD, Korelitz demonstrated that
combination therapy may preclude the need for additional surgery in CD patients with fistulas. 1. Judge TA, Lichtenstein GR. Treatment of fistulizing Crohn’s disease. Gastroenterol
Clinics North Am.
2. Present DK, Korelitz BI, Wisch N, Glass JL, Sachar DB, Pasternack BS. Treatment
of Crohn’s disease with 6-mercaptopurine: a long-term randomized double blind study. N Engl J Med.
3. Korelitz BI, Present DH. Favorable effect of 6-mercaptopurine on fistulae of Crohn’s
disease. Dig Dis Sci.
4. Markowitz JF. Therapeutic efficacy and safety of 6-mercaptopurine and azathioprine
in patients with Crohn’s disease. Rev Gastroenterol Dis.
5. Korelitz BI, Adler DJ, Mendelsohn RA, Sacknoff AL. Long-term experience with 6-
mercaptopurinein the treatment of Crohn’s disease. Am J Gastroenterol.
6. Dubinsky MC. Optimizing immunomodulator therapy for inflammatory bowel
disease. Curr Gastroenterol Rep.
7. Faber SM, Korelitz BI. Experience with Eudragit-S-coated mesalamine (Asacol) in
inflammatory bowel disease: an open study. J Clin Gastroenterol.
8. Hanauer SB, Korelitz BI, Rutgeerts P, etc. Postoperative maintenance of Crohn’s
disease remission with 6-mercaptopurine, mesalamine, or placebo: a 2-year trial.
Targan received funds from CCFA from 1981 to 1982 to study the cytotoxicity of
natural killer (NK) cells in normal and IBD intestinal mucosa.
In an early study by Targan and other investigators (1), two systems of antibody
(antitetanus toxoid) suppression, one of which appeared to be mediated by NK cells. Shortly thereafter, Deem and Targan (2) delineated the sequence in which an NK-derived cytolytic factor (NKCF) induces cytolysis that indicated that this process is strongly influenced by the presence of gluteraldehyde.
Shortly thereafter, a Targan team found that 6-mercaptopurine (6-MP) could inhibit
NK-cell cytolytic activity in patients with CD. Until then, spontaneous cytotoxic activity had not been observed in the human gut. Another Targan team, after identifying NK-positive lymphocytes within the lamina propria of the gut (4), proposed that such activity might not have been recognized or linked with NK-cell activity previously because NK cells in the gut are phenotypically different from those in the peripheral blood.
The cytolytic activity of NK cells was clarified further by 1987, when Targan and
colleagues demonstrated that phospholipase A2 (PA2) inhibitors also inhibited NK-mediated cytotoxicity. They suggested that PA2 may also modulate the surface of NK cell targets to uncover a secondary “trigger” that facilitates cytolytic activity (5). Eventually PA2 activity was found to correlate with tumor necrosis factor (TNF)-alpha activity, such that TNF expression was apparently activated by PA2 (6), TNF apparently triggered PA2 activity (7), and substances that inhibited PA2 activity apparently also blocked TNF activity in a dose-dependent manner (8).
In 1997, a Targan team investigated the role of a TNF-alpha antibody in patients with
CD (9, 10). This antibody—a chimeric monoclonal antibody known as cA2—was given to 108 patients with moderate to severe CD in a 12-week multicenter, double-blind, placebo controlled trial. A 61% clinical response was seen by week 2 and remained significantly greater than the response in the placebo group throughout the study. By week 4, a third of the active treatment patients were in remission.
This antibody is currently formulated as infliximab (Remicade), which is now
indicated for moderate to severe CD and for fistulizing CD (11). 1. Brieva JA, Targan S, Stevens RH. NK and T cell subsets regulate antibody
production by human in vivo antigen-induced lymphoblastoid B cells. J Immunol.
2. Deem RL, Targan SR. Sequential substages of natural killer cell-derived cytolytic
factors (NKCF)-mediated cytolysis as defined by gluteraldehyde modulation of the target cell. J Immunol.
3. Brogan M, Hiserodt J, Oliver M, Stevens R, Korelitz B, Targan S. The effect of 6-
mercaptopurine on natural kill-cell activities in Crohn’s disease. J Clin Immunol.
4. Shanahan F, Brogan M, Targan S. Human mucosal cytotoxic effector cells.
5. Deem RL, Britvan LJ, Targan SR. Definition of a secondary target cell trigger
during natural killer cell cytotoxicity: possible role of phospholipase A2. Cell Immunol.
6. Mohri M, Spriggs Dr, Kufe D. Effects of lipopolysaccharide on phospholipase A2
activity and tumor necrosis factor expression in HL-60 cells. J Immunol.
7. Kharbanda S, Nakamura T, Datta R, Sherman ML, Kufe D. Induction of monocytic
differentiation by tumor necrosis factor in phorbol ester-resistant KG-1a cells. Cancer Commun.
8. Sherman ML, Weber BL, Datta R, Kufe DW. Transcriptional and posttranscriptional
regulation of macrophage-specific colony stimulating factor gene expression by tumor necrosis factor: involvement of arachidonic acid metabolites. J Clin Invest.
9. Targan SR, Hanauer SB, van Deventer SJH, et al. A short-term study of chimeric
monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn’s disease. New Engl J Med.
10. Hendrickson BA, Gokhale R, Cho JH. Clinical aspects and pathophysiology of
inflammatory bowel disease. Clin Microbiol Rev.
11. Remicade (infliximab for IV Injection) Prescribing Information. Malvern, Pa:
MARKOWITZ, JAMES F, MD
Dr. Markowitz received funds from CCFA from 1991 through 1994 to develop a
prospective, double-blind, multicenter, placebo-controlled trial of 6-mercaptopurine and corticosteroids in children and adolescents with newly diagnosed CD.
Prior to the start of this project, the long-term efficacy of 6-MP in adolescents with
intractable CD was not clearly established. Markowitz and colleagues conducted a study in adolescents (N=36) who had been taking 6-MP for at least 6 months and had been intractable to other IBD agents, antibiotics, and nutrition support for approximately 5 years before starting 6-MP therapy. During the first year of treatment, patients exhibited a higher Lloyd-Still disease activity score and improvements in physical exam, nutrition, laboratory tests, and general activity scores. Annual hospitalization rates also declined (1).
In 2000, the Markowitz team conducted the first controlled trial of 6-MP/prednisone
combination therapy versus prednisone monotherapy in children with steroid-dependent CD. They found that 6-MP significantly reduced the need for prednisone and prolonged the duration of remission (3). The adverse events were similar to those seen in adults, including the increased risk for cancer. Concern over this and other adverse effects may be avoided in the future using metabolite tests (the thiopurine methyltransferase genotype/phenotype test and the 6-MP metabolite test) to optimize therapy, detect noncompliance, and reduce the risk for toxicity associated with this drug (4,5).
Despite the apparent efficacy and safety of this drug, continued evaluation is
warranted, given the recent controversy over the management of CD in children. American pediatric gastroenterologists appear to be comfortable prescribing immunomodulator drugs for children younger than 5 years (6) and prefer to start therapy in children with steroids and azathioprine (the parent drug of 6-MP), their Western European counterparts prefer to start with nutrition therapy before progressing to budesonide or steroids, at least in children with mild to moderate disease (7). Continued discussions in this area may help the physicians worldwide to reach a consensus. 1. Markowitz J, Rosa J, Grancher K, Aiges H. Daum F. Long-term 6-mercaptopurine
treatment in adolescents with Crohn’s disease. Gastroenterology.
2. Markowitz J, Grancher K, Rosa J, Aiges H, Daum F. Growth failure in pediatric
inflammatory bowel disease. J Pediatr Gastroenterol Nutr.
3. Markowitz J, Grancher K, Kohn N, Lesser M, Daum F. A multicenter trial of 6-
mercaptopurine and prednisone in children with newly diagnosed Crohn’s disease. Gastroenterology.
4. Markowitz JF. Therapeutic efficacy and safety of 6-mercaptopurine and azathioprine
in patients with Crohn’s disease. Rev Gastroenterol Dis.
5. Ringheanu M, Markowitz J. Inflammatory bowel disease in children. Curr Treat
6. Markowitz J, Grancher K, Kohn N, Daum F. Immunomodulatory therapy for
pediatric inflammatory bowel disease: changing patterns of use: 1990-2000. Am J Gastroenterol.
7. Levine A, Milo T, Buller H, Markowitz J. Consensus and controversy in the
management of pediatric Crohn disease: an international survey. J Pediatr Gastroenterol Nutr.
ROTTER, JEROME I, MD
Dr. Rotter received CCFA funding from 1992 through 1994 to investigate the role of
molecularly defined HLA class II genes in IBD.
At that time, few studies of HLA class II genes in patients with CD or UC were
available (1). Those that were available had been carried out using serological techniques and had inconclusive results. When those techniques were replaced with molecular genotyping and allele-specific oligonucleotide hybridization, the investigators discovered a positive relationship between the HLA DR2 allele and UC and a positive association with the HLA DR1 and HLA DQw5 alleles and CD.
Previously, it had been observed that antineutrophil cytoplasmic antibodies (ANCAs)
are also associated with UC (3), suggesting a disturbance in immune regulation in UC (2). The investigators in that study also found that patients with UC were likely to demonstrate a link between ANCA and DR2, which suggests that a subset of UC patients may be genetically susceptible to an immune defect that serves as the basis for the disease (2). 1. Toyoda H, Wang SJ, Yang HY, et al. Distinct associations of HLA class II genes
with inflammatory bowel disease. Gastroenterology.
2. Yang H, Rotter JI, Toyoda H, et al. Ulcerative colitis: a genetically heterogeneous
disorder defined by genetic (HLA class II) and subclinical (antineutrophil cytoplasmic antibodies) markers. J Clin Invest
3. Vasiliauskas EA, Plevy SE, Landers CJ, et al. Perinuclear antineutrophil cytoplasmic
antibodies in patients with Crohn’s disease define a clinical subgroup. Gastroenterology.
Dr. Sartor was funded by the CCFA from 1987 through 1989 to study the role of
bacterial cell walls in the pathogenesis of CD.
The potential contribution of macromolecules crossing normal and injured intestinal
tissues to intestinal inflammation had been discussed previously (1-3). Peptidoglycan-polysaccharide (PG-PS) complexes within bacterial cell walls had also been recognized as being responsible for the outcome of inflammation and immunomodulation in granulomas that follow bacterial infection, but their uptake across the intestinal epithelium had not been investigated.
The Sartor team decided to investigate this phenomenon by studying rats in which the
induction of colonic injury was followed by injection into the cecum of a small amount of 125I-labeled purified PG-PS fragments obtained from Group A Streptococcus pyogenes
organisms (4). The results were dramatic: all of the rats developed signs of illness within 24 hours. Illness was indicated by gross evidence (surface hemorrhages near the site of injection and on focal areas of the transverse and descending colon and rectum), microscopic evidence (eg, marked thickening of the lamina propria and dense PMN infiltration), and systemic distribution, indicated by elevated levels of radioactivity in the liver, spleen and mesenteric lymph nodes. Based on these findings, the investigators suggested that PG-PS derived from the normal enteric flora may induce or sustain inflammation within the intestines and in extraintestinal tissue in patients with CD or UC.
Evidence of the systemic spread of PG-PS-induced intestinal inflammation was
supported further by a subsequent study of rats in which intestinal injury was induced in the jejunum by means of a surgically created blind loop, within which a proliferation of anaerobic bacteria occurred. The results of these two tests may not be completely equivalent, because immunoreactivity was measured in this study by serological and histological tests, only. However, histological evidence of inflammation within the lamina propria, hypertrophy of the muscle layers of the gut lining, and measured changes in luminal PG-PS and anti-PG antibodies for 3 classes of immunoglobulins (IgG, IgM, and IgA, whose plasma levels did not change) strongly implicate PG-PS as the inducer of the inflammatory process (5).
Based on this evidence and evidence from subsequent studies of the role of bacteria in
intestinal inflammation, Sartor has recommended that the goals of IBD therapy include reduced exposure to luminal bacterial antigens (ie, antibiotic therapy) and correction of the abnormal immune response to gut antigens (6). Antibiotics have generally been reserved for infectious complications of IBD rather than as a component of the primary treatment regimen (7). Currently, metronidazole and ciprofloxacin are frequently used (8), despite a lack of rigorous trials (8,9) or evidence of significant benefit over placebo or sulfasalazine (8). Sartor has suggested that evidence from rodent studies provide a rationale for treating human IBD with antibiotics (7). The evidence provided by his CCFA-funded research may have paved the way for developing a rationale for rigorous controlled trials of antibiotics to ensure that they can be safely and effectively incorporated into standard primary therapy for IBD. 1. Reinhardt MC. Macromolecular absorption of food antigens in health and disease.
2. Walker WA. Antigen uptake in the gut: immunologic implications. Immunol Today.
3. Walker WA, Isselbacher KJ. Uptake and transport of macromolecules by the
intestine: possible role in clinical disorders. Gastroenterology.
4. Sartor RB, Bond TM, Schwab JH. Systemic uptake and intestinal inflammatory
effects of luminal bacterial cell wall polymers in rats with acute colonic injury. Infection and Immunity.
5. Lichtman SN, Keku J, Schwab JB, Sartor RB. Evidence for peptidoglycan absorption
in rats with experimental small bowel bacterial overgrowth. Infection and Immunity.
6. Sartor RB. Pathogenesis and immune mechanisms of chronic inflammatory bowel
diseases. Am J Gastroenterol.
7. Isaacs KL, Sartor RB. Treatment of inflammatory bowel disease with antibiotics.
Gastroenterol Clin North Am.
8. Bebb JR, Scott BB. Systematic review: how effective are the usual treatments for
Crohn’s disease? Aliment Pharmacol Ther.
9. Sartor RB. Therapeutic manipulation of the enteric microflora in inflammatory bowel
diseases: antibiotics, probiotics, and prebiotics. Gastroenterology.
ELSON, CHARLES O, MD
Dr. Elson was funded by the CCFA from 1981 through 1983 to investigate T-cell
regulation of immunoglobulin synthesis in IBD.
In an early study, the Elson team sought to determine whether patients with CD have
a defect in immune regulation by evaluating suppressor T-cell activity in patients with mild or inactive disease (1). Their in vitro studies indicated that these patients do not have a deficiency in suppressor T cells; indeed, the suppressor T-cell population markedly inhibited IgM synthesis.
Shortly thereafter, the Elson team published a report of their in vitro study of T cell
activity during a mixed lymphocyte reaction (2). They found that T cells that had been stimulated by B cells or macrophages were able to suppress proliferation and immunoglobulin synthesis. The B-cell or macrophage-stimulated T-cell activity observed here led the investigators to believe they had stumbled upon a negative feedback mechanism involved in regulating the immune response.
The next step would be to determine whether these early findings—which were
performed on elements obtained from peripheral blood—would also be observed in gut tissue. The Elson team evaluated the T-cell immune regulatory effects (suppression or “help”) in T cells obtained from intestinal lamina propria tissue that was isolated from patients with CD (3). As in the previous two studies, immunoglobulin synthesis was stimulated by adding pokeweed mitogen to the culture. Additionally, helper T-cell activity was elicited by adding normal peripheral blood cells to the cultures containing lamina propria T cells, and suppressor T-cell activity was elicited by adding B cells to cultures containing irradiated normal T cells (x-irradiation eliminated suppressor T-cell activity in an earlier study ). Suppressor T-cell activity was not significant in any of the cocultures, whether the cells were obtained from healthy controls or activity inflamed CD tissue. The investigators concluded that T-cell immune regulatory activity in the gut is carried out primarily by helper T cells, rather than by suppressor T cells, as was seen in the peripheral blood.
Finding that the immune response in gut tissue may allow for immunoglobulin
production led Elson to speculate about the possibility of developing an intestinal vaccine (4). The basic requirements for an enteric vaccine are (a) the ability to trigger the production of adequate amounts of intestinal IgA antibodies; (b) the use of antigens that can induce neutralizing antibodies, and (c) the use of an effective antigen delivery system (5).
In their search for the types of helper T cells and cytokines involved in antigen uptake
and presentation in the gut, Elson and colleagues found two helper T-cell subsets: Th1 cells—which are involved mainly in cell-mediated immunity and help produce IL-2, IFN-gamma, and TNF-beta—and Th2 cells, which regulate and promote B-cell responses and help produce several interleukins, including IL-5, IL-6, both of which trigger surface B cells to secrete IgA. (6). They also discovered that the GI lamina propria has a relatively high concentration of IL-5-producing Th2 cells and that these cells are stimulated primarily though the oral route (as opposed to Th1 cells, which are stimulated primarily through the systemic route). Additionally, time-course and dose-response studies during this trial indicated that responses to antibody exposure develop according to different sets of kinetics for oral versus serum routes of administration (7).
This led investigators to look for the most effective route of administration. When
tetanus toxin (TT) was administered through an indwelling intraperitoneal catheter, high levels of anti-TT antibody-secreting cells were detected in the general circulation and the peritoneal cavity. The predominant immunoglobulin elicited was IgG (80%), rather than the more critically important IgA. Additionally, TT failed to elicit a salivary response. Given that an intestinal antigen is likely to reach the gut by the oral route, the inability to elicit an antibody response in the oral cavity put the patient at risk for prolonged inflammation (8).
Elson was on the first research team to find evidence of a circulation route by which
newly activated antigen-specific intestinal T cells return to the gut (10). They also found that activated T cells complete this circuit--through mesenteric lymph nodes, the lymphatics, and blood—and return to the gut guided by cell surface homing receptors (particularly alpha4beta7-integrin). They also discovered that the site of antigen presentation determined whether such homing receptors are expressed or not.
Thereafter, several other investigators searched for a delivery system that could allow
oral agents to “survive” the destructive nature of the GI tract, reach the mucosa, and remain there long enough to take effect. Lavelle proposed the use of bioadhesive molecules (eg, lectins) that can recognize epithelial cell surface receptors and thus reach specific regions of the gut (11). Clark and others suggested synthetic delivery particles that can interact with antigen-sampling M cells (12). Zho and Neutra (13) suggested using liposomes (which are quite effective at inducing mucosal IgA responses) that have been modified to withstand the harsh intestinal environment and still interact with M cells. Lo indicated that some investigators are currently looking for genes that might help determine mucosal immunity and thus ensure that immune responses are directed against pathogen-associated targets, only (14). Gene expression studies have led to the discovery of novel receptors of unknown function on the apical membrane of M cells within Peyer’s patches. Ligands that are known to trigger pathways used by certain pathogens to invade the intestinal wall are being used to determine the functions of the novel receptors. These ligands may eventually serve as models for developing antigen-loaded nanoparticles capable of binding at these sites to neutralize specific antigens (15). Furthermore, continued investigation of proinflammatory cytokine activity may pave the way to developing a vaccination that takes advantage of host defenses to block TNF-alpha activity and thus modulate the immune response to the bacterial flora in the gut (16). 1. Elson CO, Graeff AS, James SP, Strober W. Covert suppressor T cells in Crohn’s
2. James SP, Yenokida GG, Graeff AS, Elson CO, Strober W. Immunoregulatory
function of T cells activated in the autologous mixed lymphocyte reaction. J Immunol.
3. Elson CO, Beagley KW, Sharmanov AT. Hapten-induced model of murine
inflammatory bowel disease: mucosa immune responses and protection by tolerance. J Immunol.
4. Bickston SJ, Comerford LW, Cominelli F. Future therapies for inflammatory bowel
disease. Curr Gastroenterol Rep.
5. Yuan L, Saif LJ. Induction of mucosal immune responses and protection against
enteric viruses: rotavirus infection of gnotobiotic pigs as a model. Vet Immunol Immunopathol.
6. McGhee JR, Fujihashi K, Xu-Amano J, Jackson RJ, Elson CO, Beagley KW, Kiyono
7. Xu-Amano J, Kiyono H, Jackson RJ, et al. Helper T cell subsets for immunoglobulin
A responses: oral immunization with tetanus toxoid and cholera toxin as adjuvant selectively induces Th2 cells in mucosa associated tissues. J Exp Med.
8. Jackson RJ, Fujihashi K, Xu-Amano J, Kiyono H, Elson CO, McGhee JR. 9. Lue C, van den Wall Bake AW, et al. Intraperitoneal immunization of human
subjects with tetanus toxoid induces specific antibody-secreting cells in the peritoneal cavity and in the circulation, but fails to elicit a secretory IgA response. Clin Exp Immunol.
10. Kantele A, Zivny J, Hakkinen M, Elson CO, Mestecky J. Differential homing
commitments of antigen-specific T cells after oral or parenteral immunization in humans. J. Immunol.
11. Lavelle EC. Targeted delivery of drugs to the gastrointestinal tract. Crit Rev Ther
Drug Carrier Syst.
12. Clark MA, Jepson MA, Hirst BH. Exploiting M cells for drug and vaccine delivery.
Adv Drug Deliv Rev.
13. Zho F, Neutra MR. Antigen delivery to mucosa-associated lymphoid tissues using
liposomes as a carrier. Biosci Rep.
14. Lo D. Exploiting immune surveillance mechanisms in mucosal vaccine development.
Expert Opin Biol Ther.
15. Brayden DJ, Baird AW. Apical membrane receptors on intestinal M cells: potential
targets for vaccine delivery. Advanced Drug Delivery Reviews.
16. Bickston SJ, Comerford LW, Cominelli F. Future therapies for inflammatory bowel
disease. Curr Gastroenterol Rep.
CHO, JUDY H, MD
Dr. Cho received funding from CCFA from 1997 through 1998 to conduct genetic
A substantial amount of epidemiological data had been collected prior to that time
suggesting that genetic susceptibility contributes to the development of IBD (1,2). This inspired several investigators to search for specific chromosomal loci that confer IBD susceptibility: • Mirza and colleagues published the results of their gene-mapping studies, through
which they found a CD susceptibility gene (IBD1
) on chromosome 16 and evidence that this gene may also contribute to UC susceptibility (2).
• Duerr and colleagues (3) attempted to find a link between IBD and chromosome 12,
as was done in a British genome screen. They selected 122 white American families that included 208 IBD-affected relative pairs. Given the small sets of affected relatives (ie, relative pairs), they carried out a nonparametric analysis (useful when there is a relative lack of evidence for a Mendelian inheritance pattern or when several genes of low to moderate penetrance may be involved ) and a transmission/disequilibrium test (TDT; useful when multi-allelic markers are present ) to confirm the British findings.
• Curran and colleagues (6) performed nonparametric analyses of data gathered from a
large group of independent European families to demonstrate a link to IBD on chromosomes 12 and 16.
• Neurath and colleagues (7) observed high levels of the transcription factor NK-kappa
B in lamina propria macrophages of patients with CD or UC, as well as the consequent increase in the production of several proinflammatory cytokines (IL-1, IL-6, and TNF-alpha) as well as the protein known as p65. They also noted that a specific antisense molecule can downregulate p65 to significantly reduce the production of these cytokines in IBD. These findings suggest the possibility of a molecular approach to patients with IBD.
• Hugot and Thomas (8) reported the findings of several groups who used genome
screens (9) not only to confirm the links between IBD and chromosomes 12 and 16, but also to identify additional potential links between IBD and chromosomes 1, 3, 4, 7, 11, 15, and X.
• Hampe and colleagues (10) used a genome-wide search for susceptibility loci to
confirm the previously identified link between IBD and 7 chromosomes and to identify 3 additional chromosomes (6, 10, and 22) that might contain genes that predispose individuals to this disease. Of particular interest were the links to chromosome 6p, which suggest an association with human leukocyte antigen and TNF genes, and the suggestion that the link with the X chromosome, which suggests an association with the Ullrich-Turner syndrome.
Others have sought specific genes that confer genetic susceptibility to IBD, including the following: • Parkes and associates applied the TDT (5) and affected sib-pair test (5) to data from
198 pairs of siblings with IBD and determined that the gene encoding IL-2 may contribute to UC susceptibility (11)
• Noting that an imbalance between IL-1 beta (IL-1 beta) and the IL-1 receptor
antagonist (IL-1ra) may play a role in the pathogenesis of IBD, Stokkers and colleagues (12) studied allelic frequencies for IL-1 beta and IL-1ra genes in patients with IBD to determine whether there was a relationship between allelic variants and cytokine production. They found a relationship between UC and several infrequent alleles (Taq1 and Mwo1), but the pathogenicity of this finding was not clear.
• The Stokkers team (13) also studied the role of HLA class II genes in IBD, because
the products of these genes play important roles in the immune response. A literature search revealed that UC and CD are each associated with specific HLA class II phenotypes. Additional research may reveal the contribution of these genes to IBD susceptibility.
The search for specific genes responsible for IBD susceptibility expanded exponentially over the following years. By 2001, researchers had identified a strong candidate within chromosome 16—NOD2.
The gene product normally activates the transcription factor NK-kappa B, thereby allowing the cell to respond to bacterial lipopolysaccharides. Using TDT (5) and case-control analysis, the Ogura team (of which Dr. Cho was a member) determined that same year that NOD2
undergoes a frameshift mutation through a cytosine insertion in patients with CD. These findings suggest that NOD2 plays a crucial role in CD susceptibility and suggest that a relationship exists between an innate immune response and components of the bacterial cell wall that contribute to this disease (14). In 2003, Cho indicated that a gene on chromosome 16 codes for NOD2/CARD15, a protein that is involved in the immune response to bacterial infection (16), and that three mutations of that gene appear to be independently associated with CD, collectively conferring a 15% to 20% risk for familial CD. Cho also indicated that NOD2 presents an increased risk for ileal disease and an earlier age of disease onset. Subsequently, Drs Cho and Dr Bonen indicated that NOD2/CARD15 is expressed on peripheral blood monocytes (17). They also indicated that three polymorphisms within the gene for this protein complex contain the code for CD, especially in individuals of European descent. Having one copy of a risk allele increases the risk for CD 2- to 4-fold in these individuals; having two copies increases the risk 20- to 40-fold. As a member of the Brant research team (18), Dr Cho helped determine that carrying two of these mutations increased the risk for early onset of disease, ileal involvement, and the development of strictures or non-perianal fistulas. As part of the Ogura team, Cho was part of the effort to find a link between NOD2 mutations and ileal disease. That laboratory developed a monoclonal antibody against NOD2, then used it to detect NOD2 expression in terminal ileal Paneth cells, specifically in the cytosol near granules that contained antimicrobial peptides, and in the epithelial layer of ileal villi and the colon. This protein was found in both patients and controls and, thus, may help regulate Paneth cell-mediated responses to intestinal bacteria (19).
Dr Cho has continued to explore the genetic mechanisms for IBD susceptibility. In
2004, she identified post-transcriptional dependence of IL-1 beta on NOD2/CARD15 suggesting that a signaling defect may be the underlying cause of pathogenesis in CD (20). She also explored several new genes believed to contribute to CD.
Her work may bring investigators closer to identifying the earliest pathways involved in IBD pathogenesis which, in turn, may reveal potential novel therapeutic targets.
1. Bickston SJ, Comerford LW, Cominelli F. Future therapies for inflammatory bowel
disease. Curr Gastroenterol Rep.
2. Mirza MM, Lee J, Teare D, Hugot JP, et al. Evidence of linkage of the inflammatory
bowel disease susceptibility locus on chromosome 16 (IBD1) to ulcerative colitis. J Med Genet.
3. Duerr RH, Barmada MM, Zhang L, et al. Linkage and association between
inflammatory bowel disease and a locus on chromosome 12. Am J Hum Gent.
4. Whittemore AS, Tu IP. Simple, robust linkage tests for affected sibs. Am J Hum
5. McGinnis RE. Hidden linkage: a comparison of the affected sib pair (ASP) test and
transmission/disequilibrium test (TDT). Ann Hum Genet.
6. Curran ME, Lau KF, Hampe J, et al. Genetic analysis of inflammatory bowel disease
in a large European cohort supports linkage to chromosomes 12 and 16. Gastroenterology.
7. Neurath MF, Fuss I, Schurmann G, et al. Cytokine gene transcription by NF-kappa B
members in patients with inflammatory bowel disease. Ann NY Acad Med.
8. Hugot JP, Thomas G. Genome-wide scanning inflammatory bowel diseases. Dig Dis.
9. Xu J, Wiesch DG, Meyers DA. Genetics of complex human diseases: genome
screening, association studies, and fine mapping. Clin Exp Allergy.
10. Hampe J, Schreiber S, Shaw SH, et al. A genome-wide analysis provides evidence
for novel links in inflammatory bowel disease in a large European cohort. Am J Hum Genet.
11. Parkes M, Satasangi J, Jewell D. Contribution of the IL-2 and IL-10 genes to
inflammatory bowel disease (IBD) susceptibility. Clin Exp Immunol.
12. Stokkers PC, van Aken BE, Basoski N, Reitsma PH, Tytgat GN, van Deventer SJ.
Five genetic markers in the interleukin 1 family in relation to inflammatory bowel disease. Gut.
13. Stokkers PC, Reitsma PH, Tytgat GN, van Deventer SJ. HLA-DR and –DQ
phenotypes in inflammatory bowel disease: a meta-analysis. Gut.
14. Ogura Y, Bonen DK, Inohara N, et al. A frameshift mutation in NOD2 associated
with susceptibility to Crohn’s disease. Nature.
15. Cho JH. Significant role of genetics in IBD: the NOD2 gene. Rev Gastroenterol
16. Bonen DK, Cho JH. The genetics of inflammatory bowel disease. Gastroenterology.
17. Brant SR, Picco MF, Achkar JP, et al. Defining complex contributions of
NOD2/CARD15 gene mutations, age at onset, and tobacco use on Crohn’s disease phenotypes. Inflamm Bowel Dis.
18. Ogura Y, Lala S, Xin W, et al. Expression of NOD2 in Paneth cells: a possible link
to Crohn’s ileitis. Gut.
19. Li J, Moran T, Swanson E, et al. Regulation of IL-8 and IL-1beta expression in
Crohn’s disease associated NOD2/CARD15 mutations. Hum Mol Genet.
20. Cho JH. Advances in the genetics of inflammatory bowel disease. Curr
Dr. Das was funded to study the pathogenesis of IBD (1981-1983) and the
During the first funding period, Dr. Das worked with Dr. Nagai to clarify the role of a
disease-specific colonic tissue-bound antibody (CCA) they identified previously in patients with UC (1). Specifically they improved their methods of extracting and purifying intact CCA-IgG. They then demonstrated that this molecule binds to colonic mucosal tissue in UC but not in CD or in normal colonic tissue from patients with carcinoma (2).
Das and another colleague, Dr. Takahashi, then characterized a colonic protein that is
recognized by CCA-IgG. Using immunorecognition studies, affinity-column chromatography, transblot analysis, electrophoresis, and an iodinated CCA-IgG probe on a variety of tissues obtained from patients with UC, Crohn’s colitis, or myeloma, they found CCA-IgG was consistently bonded to a 40-kD protein in colon tissue extracts. This bond was found most frequently in tissue obtained from patients with symptomatic UC and never in colonic tissue obtained from patients with Crohn’s colitis (3). These findings suggest the existence of an organ-specific colonic “autoantigen” that might be able to initiate an IgG antibody response in patients with UC.
To learn more about this molecule, Das and colleagues developed monoclonal
antibodies against it. Antibody studies allowed them to localize the antibody-40kD antigen interaction exclusively to colonic epithelial cells, specifically within the crypt and on the luminal surface of the epithelium in this study (4), primarily along the basolateral surfaces in a murine study (5), and in both membrane regions in another study in human tissue (6). Such studies also allowed these investigators to discover that • This antibody-antigen interaction occurred more frequently in colon tumor cells and
that its frequency was not affected by interferon gamma (IFN-gamma) (7)
• The 40 kDa molecule is involved in antibody-dependent cellular cytotoxicity (ADCC)
against colon cancer cells by UC serum (8)
• 40 kDa expression in colonic cells is accompanied by the expression of intercellular
adhesion (ICAM) molecules (especially ICAM-1), which may be involved in the localization of leukocytes to the colonic epithelium during UC (9)
Years after the CCFA funding ended, the investigators continued their investigation
of the 40 kDa molecule in UC: • They gave it a name: P40 • They discovered that it can be found in the goblet cells of normal ileal and proximal
colonic tissue, as well as in enterocytes, where its concentration increases in a distal direction (11)
• They found it in several noncolonic areas, including the gall bladder, major bile ducts,
fallopian tubes, and epidermis (11), as well as nonpigmented ciliary epithelial cells and chondrocytes (12)—all of which suggests potential areas for extraintestinal complications of UC
• They discovered that P40 is a member of the tropomyosin family (10). The most
common tropomyosin isoform found in the intestine—human tropomyosin (hTM) isoform 5 (hTM5) (13)—is an intracellular protein that can be externalized in the colonic epithelium but not in the small intestine(14). hTM5 has such a strong
association with a membrane-bound colon epithelial protein that is suspected of being involved in its transport to the cell surface and may serve as a target autoantigen in UC (14)
• They named the anti-P40 antibody—mAb Das-1(15)—and found that it reacts with
liver tissue and is expressed in correlation with the expression of specific liver molecules, including glycogen (15)
• They found that B cells in the lamina propria produce IgG against hTM5, most
• They identified hTM5 as a colon epithelial cell antigen that can trigger a significant
Thus far, Das and colleagues have produced a substantial amount of information
about several components of the autoimmune activity in UC. Additional studies of the antibody and its target (as well as the cellular components responsible for its upregulation and presentation on the cell surface) are needed to bring these investigators closer to finding an effective immunologic approach to therapy. 1. Das KM, Dubin R, Nagai T. Isolation and characterization of colonic tissue-bound
antibodies from patients with idiopathic ulcerative colitis. Proc Natl Acad Sci USA.
2. Nagai T, Das KM, Detection of colonic antigen(s) in tissues from ulcerative colitis
using purified colitis colon tissue-bound IgG (CCA-IgG).
3. Takahashi F, Das M. Isolation and characterization of a colonic autoantigen
specifically recognized by colon tissue-bound immunoglobulin G from idiopathic ulcerative colitis. J Clin Invest.
4. Das KM, Sakamaki S, Vecchi M, Diamond B. The production and characterization
of monoclonal antibodies to a human colonic antigen associated with ulcerative colitis: cellular localization of the antigen by using the monoclonal antibody. J Immunol.
5. Das KM, Sakamaki S, Vecchi M. Ulcerative colitis: specific antibodies against a
colonic epithelial Mr 40,000 protein. Immunol Invest.
6. Das KM, Vecchi M, Sakamaki S. A shared and unique epitope(s) on human colon,
skin, and biliary epithelium detected by a monoclonal antibody. Gastroenterology.
7. Das KM, Squillante L, Robertson F. Expression of the 40 kD protein in DLD-1 colon
cancer cells and the effect of cytokines. Clin Exp Immunol.
8. Biancone L, Das KM, Roberts AI, Ebert EC. Ulcerative colitis serum recognizes the
M(r) 40K protein on colonic adenocarcinoma cells for antibody-dependent cellular cytotoxicity. Digestion.
9. Das KM, Squillante L, Robertson FM. Amplified expression of intercellular adhesion
molecule-1 (ICAM-1) and M(r) 40K protein by DLD-1 colon tumor cells by interferon gamma. Cell Immunol.
10. Das KM, Dasgupta A, Mandal A, Geng X. Autoimmunity to cytoskeletal protein
tropomyosin: a clue to the pathogenetic mechanism for ulcerative colitis. J Immuno.
11. Halstensen TS, Das KM, Brandtzaeg P. Epithelial deposits of immunoglobulin G1
and activated complement colocalise with the M(r) 40 kD putative autoantigen in ulcerative colitis. Gut.
12. Bhagat S, Das KM. A shared and unique peptide in the human colon, eye, and joint
detected by a monoclonal antibody. Gastroenterology.
13. Geng X, Biancone L, Dai HH, et al. Tropomyosin isoforms in intestinal mucosa:
production of autoantibodies to tropomyosin isoforms in ulcerative colitis. Gastroenterology.
14. Kesari KV, Yoshizaki N, Geng X, Lin JJ, Das KM. Externalization of tropomyosin
isoform 5 in colon epithelial cells. Clin Exp Immunol.
15. Badve S, Logdberg L, Sokhi R, et al. An antigen reacting with das-1 monoclonal
antibody is ontogenically regulated in diverse organs including liver and indicates sharing of developmental mechanisms among cell lineages. Pathobiology.
16. Onuma EK, Amenta PS, Ramaswamy K, Lin JJ, Das KM. Autoimmunity in
ulcerative colitis (UC): a predominant colonic mucosal B cell response against human tropomyosin isoform 5. Clin Exp Immunol.
17. Taniguchi M, Geng X, Glazier KD, Dasgupta A, Lin JJ, Das KM. Cellular immune
response against tropomyosin isoform 5 in ulcerative colitis. Clin Immunol.
DUERR, RICHARD H, MD
Dr. Duerr received funding from CCFA from 2001 through 2002 to study linkage
disequilibrium patterns with a novel IBD locus on chromosome 3P.
Chromosome 3p was first identified as being likely to contain IBD susceptibility
genes in 1996 (1). Genetic screening of a total of 186 sibling pairs affected with CD and UC provided evidence of a link between IBD and 46 microsatellite markers, with 16 of the strongest markers seen in chromosomes 2, 3, 7, 12, and 15. The strongest linkage to a single marker was identified in chromosome 12. By contrast, chromosome 3 contained several markers that lie adjacent to regions containing genes that code for UC complications, eg, carcinoma of the colon and renal cell carcinoma (1), as well as two autoimmune disorders—MS and inflammatory arthritis—which suggests one or more genes involved in the inflammatory response (2). One chromosome 3p marker--D3S1076--lies near several potential IBD susceptibility genes, including the genes for cytokine receptors 2 and 5, both of which play an important role in immunoregulation (2). Neither of these receptor genes appears to play a role in the IBD phenotype, but they both reside near other potential IBD-related genes, including the gene for lactotransferrin (which may play a role in neutrophil and antibacterial activity), the ubiquitin complex (which may be involved in antigen processing), the cathelicidin antimicrobial peptide and the TRAF interacting protein (which play a key role in TNF-alpha signal transduction), the mitogen-activated protein kinase that is activated by protein kinase 3, and the IFN-alpha receptor (receptor 2).
Being closely associated with so many genes creates a serious research-related
challenge, however, because it presents the risk of disease-associated disequilibrium (2), ie, the observed frequency of haplotypes may not agree with the frequency predicted by multiplying the frequency of individual markers within each haplotype. Identification of links between markers and disease requires linkage analysis (3), a procedure that is used to determine the distance between the marker and the susceptibility gene. It involves an investigation of pedigree, usually by identifying families with affected sibling pairs or affected relative pairs; genotyping by polymorphisms the entire genome or certain chromosomes; and determining the approximate position of the susceptibility gene within the genome map, which involves calculating the LOD score (a non-parametric measure of distance between the susceptibility gene and marker) for several points. Linkage analysis is then followed by an association analysis of candidate genes (3).
By 2002, Duerr and colleagues were able to report their finding of a specific IBD
locus on chromosome 3p26. Evidence of linkage was set at an LOD score of 2 or more in a previous study (4); in the Duerr study, a LOD score of 3.69 was achieved for D3S1297, indicating a strong linkage between marker and disease (5).
A recent study indicates that more than 20 genomic regions have been identified as
containing IBD susceptibility loci (6). Continued work in this area may facilitate the development of genetic strategies for preventing or treating this disease. Satsangi J, Parkes M, Louis E, et al. Two stage genome-wide search in inflammatory bowel disease provides evidence for susceptibility loci on chromosomes 3, 7 and 12. Nature Genetics.
Hampe J, Lynch NJ, Daniels S, et al. Fine mapping of the chromosome 3p susceptibility locus in inflammatory bowel disease. Gut.
2001;48:191-197. Zheng C-Q, Hu G-Z, Lin L-J, Gu G-G. Progress in searching for susceptibility gene for inflammatory bowel disease by positional cloning. World J Gastroenterol.
2003;9:1646-1656. Rioux JD, Silverberg MS, Daly MJ, et al. Genome-wide search in Canadian families with inflammatory bowel disease reveals two novel susceptibility loci. Am J Hum Genet.
66;1863-1870, 2000. Duerr RH, Barmada MM, Zhang L, et al. Evidence for an inflammatory bowel disease locus on chromosome 3p26: linkage, transmission/disequilibrium and partitioning of linkage. Hum Mol Genet.
2002; 11:2599-2606. Barmada MM, Brant SR, Nicolae DL, et al. A genome scan in 260 inflammatory bowel disease-affected relative pairs. Inflamm Bowel Dis.
CHANG EUGENE B, MD
Dr. Chang received funding from CCFA from 1999 through 2002 to study barrier
During this period, Dr Chang’s team produced numerous reports of their work on
epithelial ion exchange in the intestines. Chang was among the first to characterize the intestinal Na+/H+ exchanger (NHE) in intestinal tissue (specifically, an intestinal villus-like subclone [C2bbe]) rather than in nonepithelial mutated fibroblasts (as had been the practice until 1999) (1). To measure NHE activity, he monitored the unidirectional apical uptake of 22Na+ under basal, non-acid conditions. This approach represented a dramatic change in the process of evaluating NHE activity. Previously, it was evaluated by monitoring intracellular pH, which can only approximate NHE activity and may be altered by buffers and non-NHE contributions to pH. Thus, Chang and colleagues developed a method that could significantly improve the accuracy of research findings. Using this improved technique, the Chang team found that the brush-border NHEs—NHE2 and NHE3—both localize to the C2bbe apical domain. They also found that both NHEs are regulated by second messengers, albeit through different signal transduction pathways.
The precise characterization of such exchange molecules will prove essential in
determining the role of anion secretion in IBD, either as a participant in complications (eg, diarrhea) or as a regulatory signal. For example, the Chang team found that an oxidant (monochloramine) could potentiate colonic calcium- and cAMP-stimulated chloride ion secretion through its effect on calcium-activated potassium channel conductance. This could increase the severity of diarrhea in patients with an inflamed colonic mucosa (2). They also found that short-chain fatty acids—produced by fermentation of dietary carbohydrates carried out by the bacterial flora in the colon—enhance apical NHE3 activity (but not NHE2 activity) in a time- and concentration-dependent manner and, thus, may serve as a physiological cue that allows the colon to adjust its sodium absorption rate in response to ongoing changes in dietary carbohydrate and sodium loads (3).
Another Chang team investigated the effect of IFN-gamma on ion transport across the
intestinal epithelium (4). This could be a critical component of the pathogenesis of IBD, because IFN-gamma helps regulate and promote B-cell responses and helps produce several interleukins that facilitate B-cell secretion of IgA. Chang and colleagues assessed Na+/K+-ATPase activity using the inhibitor ouabain and monitored intracellular Na+ with the Na+ ionophore monensin. They found that IFN-gamma acutely reduced Na+/K+-ATPase activity and increased the intracellular Na+ concentration and, consequently, cell volume. These effects suggest that IFN-gamma can trigger signaling events that result in the leaky, dysfunctional epithelium that is characteristic of chronic inflammation (4). The potential role of IFN-gamma in IBD diarrhea was supported by a subsequent study of NHE expression in culture and in adult rats. NHE expression was monitored by unidirectional 22Na+ influx and by changes in concentration in rat brush-border membrane vesicles; NHE protein and mRNA levels were assessed by Western and Northern blotting. The investigators found that IFN-gamma triggered downregulation of NHE2 and NHE3 expression and activity, which could result in inflammation-associated diarrhea (5).
The Chang team also investigated the intestine’s ability to adapt to new sodium
absorption requirements following extensive bowel resection. After removing 50% of the proximal rat bowel, investigators found that brush-border hydrolase activity and total cell protein per DNA was comparable to the length of bowel, but basolateral Na+/K+-ATPase activity was increased. NHE2 and NHE3 levels increased in the ileum distal to the anastomosis; their expression in the proximal colon increased only after 80% of the bowel had been removed. The investigators concluded that an increase in luminal sodium concentration in the distal bowel following a proximal resection may trigger a compensatory increase in apical NHE gene transcription and protein expression (6).
After several years of work on transmembrane ion movement, Chang and colleagues
expanded their efforts to focus on methods of protecting the integrity of the colonic epithelium. Heat shock proteins (HSPs) had been shown to be effective in this regard in animal models of septic shock (7). HSP expression had not been induced in humans because laboratory induction agents are highly toxic. Chang and colleagues discovered, however, that when glutamine is administered to rats with endotoxemia, it reduces mortality dramatically and protects against end-organ damage (7). This protection appears to be associated with a reduction in the release of at least two pro-inflammatory cytokines: TNF-alpha and IL-1 beta (8). Chang and colleagues also observed this in human peripheral blood polymorphonuclear cells (9). Importantly, it is effective when given as sepsis begins, rather than as a pretreatment (7, 8). Thus, glutamine may prove effective in therapy rather than prophylaxis only.
The gut flora may contribute to the protection afforded by glutamine by continuously
inducing the expression of HSPs on the surface of colonic enterocytes. By monitoring E coli
(10) lipopolysaccharide (LPS) and mouse colonic HSP25 levels, the Chang team found that LPS induced HSP25 induction in colonic epithelial cells and may protect the colon from injury by means of filamentous actin stabilization, both under normal and pathophysiological conditions (11). These findings were confirmed in a subsequent article by the Chang team, which reported that HSP expression in rats that had been surgically altered to achieve continuous colonization within the jejunum resulted in improved protection against oxidant-induced transmural stress (12). 1. Bookstein C, Musch MW, Xie Y, Rao MC, Chang EB. Regulation of intestinal
epithelial brush border Na(+)/H(+) exchanger isoforms, NHE2 and NHE3, in C2bbe cells. J Membr Biol.
2. Sugi K, Musch MW, Di A, Nelson DJ, Chang EB. Oxidants potential Ca(2+)- and
cAMP-stimulated Cl(-) secretion in intestinal epithelial T84 cells. Gastroenterology.
3. Musch MW, Bookstein C, Xie Y, Sellin JH, Change EB. SCFA increase intestinal
Na absorption by induction of NHE3 in rat colon and human intestinal C2/bbe cells. Am J Physiol Gastrointest Liver Physiol.
4. Sugi K, Musch MW, Field M, Chang EB. Inhibition of Na+,K+-ATPase by
interferon gamma down-regulates intestinal epithelial transport and barrier function. Gastroenterology.
5. Rocha F, Musch MW, Lishanskiy L, Bookstein C, Sugi K, Xie Y, Chang EB.
6. Musch MW, Bookstein C, Rocha F, et al. Region-specific adaptation of apical Na/H
exchangers after extensive proximal small bowel resection. Am J Physiol Gastrointest Liver Physiol.
7. Wischmeyer PE, Kahana M, Wolfson R, Ren H, Musch MM, Chang EB. Glutamine
induces heat shock protein and protects against endotoxin shock in the rat. J Appl Physiol.
8. Wischmeyer PE, Kahana M, Wolfson R, Ren H, Musch MM, Chang EB. Glutamine
reduces cytokine release, organ damage, and mortality in a rat model of endotoxemia. Shock.
9. Wischmeyer PE, Riehm J, Singleton KD, et al. Glutamine attenuates tumor necrosis
factor-alpha release and enhances heat shock protein 71 in human peripheral blood mononuclear cells. Nutrition.
10. Hendrickson BA, Gokhale R, Cho JH. Clinical aspects and pathophysiology of
inflammatory bowel disease. Clin Microbiol Rev.
11. Kojima K, Musch MW, Ropeleski MJ, Boone DL, Ma A, Chang EB. Escherichia
coli LPS induces heat shock protein 25 in intestinal epithelial cells through MAP kinase activation. Am Physiol Gastrointest Liver Physiol.
12. Arvans DL, Vavricka SR, Ren H, et al. Luminal bacterial flora determines
physiological expression of intestinal epithelial cytoprotective heat shock proteins, Hsp 25 and Hsp 72. Am J Physiol Gastrointest Liver Physiol.
2004. In print.
MAYER, LLOYD F, MD
Dr. Mayer received funding from CCFA from 1998 through 2000 to investigate the
mechanism of CD8 suppressor T-cell function induced by intestinal epithelial cells.
As early as 1990, a Mayer research team reported an unusually high proportion of T
cells with T-cell antigen receptors containing the gene product V-beta 8 in patients with CD (1). They were unable to correlate this finding with the clinical characteristics of the disease and they were not able to connect the RFLP for V-beta 8 with a specific disease. However, they did find evidence suggesting that these T cells were concentrated in diseased bowel tissues (1). They also found that the monoclonal antibody that detects V-beta 8 interacts strongly with an unidentified antigen on epithelial cells and hypothesized that an autoantigen may exist on damaged epithelial cells.
Five years later, Mayer and associates reported that the key to mucosal epithelial cells
being able to trigger CD8-positive suppressor T-cell activity depends on an epithelial cell surface non-class I molecule activating a CD8-asociated tyrosine kinase (p561ck); that activation appears to allow the CD8 molecule to bind with the T cell. This linkage appears to be essential for T-cell activation, but not for T-cell proliferation, which suggests that second signal might be necessary for such proliferation. The authors suggest that the second signal might work through the T-cell antigen receptor (2).
CD8-positive suppressor T-cell proliferation may also require a specific epithelial
surface structure. Proliferation is blocked by two epithelium-specific monoclonal antibodies--mAB B9 and mAB L12--both of which recognize a 180-kDa glycoprotein (gp180) on the epithelial membrane. gp180 appears to be capable of regulating mucosal immune responses, as it can bind with peripheral blood T cells and activate p56(lck) (3). Expectedly, gp180 is not as plentiful in inflamed intestinal tissue as it is in normal tissue, as indicated by patchy immunohistochemical staining in UC and faint to absent staining in CD. Additionally, gp180 expression is altered and p561ck activity is reduced in IBD tissue (4). Within another 2 years, Mayer and colleagues had determined that the intestinal epithelium triggers CD8-positive suppressor T cell proliferation in conjunction with p56(lck) and the T-cell receptor-associated kinase p59(fyn) (5).
Suppressor T cells are believed to promote oral tolerance in normal tissue (6). The
Mayer team tried to determine whether tolerance could be induced in patients with UC or CD by feeding them keyhole limpet hemocyanin (KLH) and attempting to raise anti-KLH antibodies through subcutaneous and booster immunization. KLH-induced T-cell proliferation was reduced in controls but enhanced significantly in patients with CD or UC. Neither oral tolerance nor antibodies to KLH could be raised in these patients. Active immunity may have been triggered in the patients with IBD, indicating a functional defect in the ability of mucosa to suppress an immune response.
Thus, through their methodical exploration of an unknown protein on the surface of
the gut epithelium, Mayer and colleagues eventually found several important keys to a crucial component of autoimmune activity in IBD and the development of oral tolerance. Continued exploration of the latter may pave the way to the development of an oral vaccine against antigens responsible for intestinal inflammation.
1. Posnett DN, Scmelkin I, Burton DA, August A, McGrath, H, Mayer LF. T cell
antigen receptor V gene usage increases in Vβ8+ T cells in Crohn’s disease. J Clin Invest.
2. Li Y, Yio XY, Mayer L. Human intestinal epithelial cell-induced CD8+ T cell
activation is mediated through CD8 and the activation of CD8-associated p561ck. J Exp. med.
3. Yio XY, Mayer L. Characterization of a 180-kDa intestinal epithelial cell membrane
glycoprotein, gp180: a candidate molecule mediating t cell-epithelial cell interactions. J Biol Chem.
4. Toy LS, Yio XY, Lin A, Honig S, Mayer L. Defective expression of gp180, a novel
CD8 ligand on intestinal epithelial cells, in inflammatory bowel disease. J Clin Invest.
5. Campbell NA, Kim HS, Blumberg RS, Mayer L. The nonclassical class I molecule
CD1d associates with the novel CD8 ligand gp180 on intestinal epithelial cells. J Biol Chem.
6. Kraus TA, Toy L, Chan L, Childs J, Mayer L. Failure to induce oral tolerance to a
soluble protein in patients with inflammatory bowel disease. Gastroenterology.
Manuel Justiniano de Freitas Quintão Em 16 de dezembro de 1955, em sua residência, à Rua Martin Lage, no Méier,desencarnou Manuel Justiniano de Freitas Quintão. Foi sócio da Federação EspíritaBrasileira durante 44 anos e ocupou-lhe a presidência em 1915, 1918, 1919 e 1929. Publicou vários trabalhos, entre os quais "O Cristo de Deus". Em 1939 escreveu a sua própria biograf
Medication deferral list (Question 4) Please tell us if you are now taking or if you have EVER taken any of these medications: • Proscar© (Finasteride) - usually given for prostate gland • Avodart© (Dutasteride) - usually given for prostate gland • Propecia© (Finasteride) - usually given for baldness. • Accutane© (Isotretinoin) - usually given for sev